Literature DB >> 26399469

Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.

Jing Zhou1, Lingfeng Qin2, Tai Yi2, Rahmat Ali2, Qingle Li2, Yang Jiao2, Guangxin Li2, Zuzana Tobiasova2, Yan Huang2, Jiasheng Zhang2, James J Yun2, Mehran M Sadeghi2, Frank J Giordano2, Jordan S Pober2, George Tellides1.   

Abstract

RATIONALE: Transplantation, the most effective therapy for end-stage organ failure, is markedly limited by early-onset cardiovascular disease (CVD) and premature death of the host. The mechanistic basis of this increased CVD is not fully explained by known risk factors.
OBJECTIVE: To investigate the role of alloimmune responses in promoting CVD of organ transplant recipients. METHODS AND
RESULTS: We established an animal model of graft-exacerbated host CVD by combining murine models of atherosclerosis (apolipoprotein E-deficient recipients on standard diet) and of intra-abdominal graft rejection (heterotopic cardiac transplantation without immunosuppression). CVD was absent in normolipidemic hosts receiving allogeneic grafts and varied in severity among hyperlipidemic grafted hosts according to recipient-donor genetic disparities, most strikingly across an isolated major histocompatibility complex class II antigen barrier. Host disease manifested as increased atherosclerosis of the aorta that also involved the native coronary arteries and new findings of decreased cardiac contractility, ventricular dilatation, and diminished aortic compliance. Exacerbated CVD was accompanied by greater levels of circulating cytokines, especially interferon-γ and other Th1-type cytokines, and showed both systemic and intralesional activation of leukocytes, particularly T-helper cells. Serological neutralization of interferon-γ after allotransplantation prevented graft-related atherosclerosis, cardiomyopathy, and aortic stiffening in the host.
CONCLUSIONS: Our study reveals that sustained activation of the immune system because of chronic allorecognition exacerbates the atherogenic diathesis of hyperlipidemia and results in de novo cardiovascular dysfunction in organ transplant recipients.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; interferons; lymphocytes; transplantation

Mesh:

Substances:

Year:  2015        PMID: 26399469      PMCID: PMC4636943          DOI: 10.1161/CIRCRESAHA.115.306932

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  66 in total

Review 1.  Managing patients with a failed kidney transplant: how can we do better?

Authors:  John S Gill
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-11       Impact factor: 2.894

2.  Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients.

Authors:  Samuel A Silver; Michael Huang; Michelle M Nash; G V Ramesh Prasad
Journal:  Transplantation       Date:  2011-07-27       Impact factor: 4.939

3.  The cardiovascular response of normal humans to the administration of endotoxin.

Authors:  A F Suffredini; R E Fromm; M M Parker; M Brenner; J A Kovacs; R A Wesley; J E Parrillo
Journal:  N Engl J Med       Date:  1989-08-03       Impact factor: 91.245

4.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

5.  Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity.

Authors:  P S Russell; C M Chase; H J Winn; R B Colvin
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

6.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.

Authors:  R L Reddick; S H Zhang; N Maeda
Journal:  Arterioscler Thromb       Date:  1994-01

7.  Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.

Authors:  Roland Jahns; Valérie Boivin; Lutz Hein; Sven Triebel; Christiane E Angermann; Georg Ertl; Martin J Lohse
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries.

Authors:  Yinong Wang; William R Burns; Paul C Y Tang; Tai Yi; Jeffrey S Schechner; Hans-Guenter Zerwes; William C Sessa; Marc I Lorber; Jordan S Pober; George Tellides
Journal:  FASEB J       Date:  2004-01-20       Impact factor: 5.191

9.  Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma.

Authors:  P S Russell; C M Chase; H J Winn; R B Colvin
Journal:  Transplantation       Date:  1994-05-15       Impact factor: 4.939

10.  Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations.

Authors:  P S Russell; C M Chase; H J Winn; R B Colvin
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

View more
  4 in total

Review 1.  Cytokines associated with immune response in atherosclerosis.

Authors:  Jiqing Ma; Jianhua Luo; Yudong Sun; Zhiqing Zhao
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 2.  Innate immune mechanisms in transplant allograft vasculopathy.

Authors:  Dan Jane-Wit; Caodi Fang; Daniel R Goldstein
Journal:  Curr Opin Organ Transplant       Date:  2016-06       Impact factor: 2.640

3.  T cells mediate cell non-autonomous arterial ageing in mice.

Authors:  Daniel W Trott; Daniel R Machin; Tam T T Phuong; AdeLola O Adeyemo; Samuel I Bloom; R Colton Bramwell; Eric S Sorensen; Lisa A Lesniewski; Anthony J Donato
Journal:  J Physiol       Date:  2021-08       Impact factor: 6.228

4.  IL-27 Rα+ cells promoted allorejection via enhancing STAT1/3/5 phosphorylation.

Authors:  Shanshan Zhao; Ting Liang; Chao Zhang; Dai Shi; Wen Jiang; Chen Su; Guihua Hou
Journal:  J Cell Mol Med       Date:  2020-08-06       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.